Rare disease pharma incentives enticing PE: 7 recent deals
SK Capital, Nordic Capital Partners and KKR are among the many PE firms looking at specialty pharma companies developing rare disease treatments.
26 July 2024•5 mins read
SK Capital, Nordic Capital Partners and KKR are among the many PE firms looking at specialty pharma companies developing rare disease treatments.
PE spots opportunities in horse healthcare: 5 deals
23 October 2026 · 3 mins read
Blackstone spots AI and low-cost interceptors opportunity with Falcata defense platform
21 October 2026 · 2 mins read
Exclusive: MSCP bets on aging water infrastructure with The Rapid Group investment
20 October 2026 · 3 mins read
PE eyes cardiometabolic care amid GLP-1 boom, outpatient shifts: 6 deals
16 October 2026 · 3 mins read
Exclusive: Vista agrees to acquire HID's PKI business unit
16 October 2026 · 3 mins read
ArchiMed’s Denis Ribon details €1.5bn fund deployment plans as AI reshapes healthcare
14 October 2026 · 4 mins read
Exclusive: ATL Partners forms Precise Aerospace & Defense platform
13 October 2026 · 3 mins read
